Profile
Daniel Lochner is currently the Chief Financial Officer at Tectonic Therapeutic, Inc. He previously worked as a Portfolio Manager at Goldman Sachs Asset Management LP from 2005 to 2019.
Additionally, he served as the Chief Financial Officer at AVROBIO, Inc. in 2024 and at Oyster Point Pharma, Inc. from 2019 to 2022.
Mr. Lochner holds an MBA from The Trustees of Columbia University in The City of New York and an undergraduate degree from the University of Richmond.
Daniel Lochner active positions
| Companies | Position | Start |
|---|
Former positions of Daniel Lochner
| Companies | Position | End |
|---|---|---|
Goldman Sachs Asset Management LP
 Goldman Sachs Asset Management LP Investment ManagersFinance Goldman Sachs Asset Management LP (GSAMLP) is a SEC-registered investment advisor headquartered in New York City. The firm is a wholly owned subsidiary of GSAM Holdings LLC, and their ultimate parent is Goldman Sachs Group, Inc. (NYSE: GS). Founded in 1988, GSAMLP provides investment solutions to a range of individual and institutional investors worldwide. | Portfolio Manager-Equities | 2019-06-30 |
| TECTONIC THERAPEUTIC, INC. | Director of Finance/CFO | - |
| OYSR POIN | Director of Finance/CFO | - |
Training of Daniel Lochner
| University of Richmond | Undergraduate Degree |
| The Trustees of Columbia University in The City of New York | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 3 |
|---|---|
Goldman Sachs Asset Management LP
Goldman Sachs Asset Management LP Investment ManagersFinance Goldman Sachs Asset Management LP (GSAMLP) is a SEC-registered investment advisor headquartered in New York City. The firm is a wholly owned subsidiary of GSAM Holdings LLC, and their ultimate parent is Goldman Sachs Group, Inc. (NYSE: GS). Founded in 1988, GSAMLP provides investment solutions to a range of individual and institutional investors worldwide. | Finance |
Oyster Point Pharma, Inc.
 Oyster Point Pharma, Inc. Pharmaceuticals: MajorHealth Technology Oyster Point Pharma, Inc. engages in the development and commercialization of pharmaceutical therapies to treat ocular surface diseases. Its product candidate, OC-01, is a nicotinic acetylcholine receptor agonist, which is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. The company was founded by Michael and is Ackermann in June 30, 2015 headquartered in Princeton, NJ. | Health Technology |
Avrobio, Inc.
 Avrobio, Inc. BiotechnologyHealth Technology AVROBIO, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firm's clinical-stage programs include Fabry, Gaucher Type 1, Hunter syndrome Gaucher Type 3, Pompe, and Cystinosis. The company was founded by Geoff Mackay, Kim Warren, Christopher Mason, and Jeffrey Medin in 2015 and is headquartered in Watertown, MA. | Health Technology |
- Stock Market
- Insiders
- Daniel Lochner
